# INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

> **NCT04116073** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 25 (actual)

## Conditions studied

- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** INCMGA00012 (PD-1 antibody)

## Key facts

- **NCT ID:** NCT04116073
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-09
- **Primary completion:** 2024-08-06
- **Final completion:** 2024-12-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116073, "INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04116073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*